Viking Therapeutics
VKTX
422 hedge funds and large institutions have $5.25B invested in Viking Therapeutics in 2024 Q3 according to their latest regulatory filings, with 94 funds opening new positions, 179 increasing their positions, 101 reducing their positions, and 57 closing their positions.
92% more call options, than puts
Call options by funds: $464M | Put options by funds: $242M
77% more repeat investments, than reductions
Existing positions increased: 179 | Existing positions reduced: 101
65% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 57
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
23% more capital invested
Capital invested by funds: $4.26B → $5.25B (+$987M)
9% more funds holding
Funds holding: 387 → 422 (+35)
2.82% more ownership
Funds ownership: 72.94% → 75.76% (+2.8%)
Top Buyers
| 1 |
Norges Bank
Oslo,
Norway
|
+$63.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$59M |
| 3 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$58.4M |
| 4 |
PA
Perceptive Advisors
New York
|
+$57.4M |
| 5 |
Morgan Stanley
New York
|
+$54.4M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$53.8M |
| 2 |
BlackRock
New York
|
-$37.9M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$37.1M |
| 4 |
Millennium Management
New York
|
-$32.3M |
| 5 |
State Street
Boston,
Massachusetts
|
-$26.3M |
VKTX Hedge Fund Activity: Q3 2024 in Review
422 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2024, worth a combined $5.25B — up 23% from $4.26B a quarter earlier.
Buyers outnumbered sellers: 94 funds opened new VKTX positions and 57 closed out — a net gain of 37 holders — while 179 added to existing stakes and 101 trimmed.
The largest buyer was Norges Bank, adding an estimated $63.8M. The largest seller was Goldman Sachs, cutting an estimated $53.8M.
- 422 institutional investors held Viking Therapeutics (VKTX) as of Q3 2024, up from 387 in Q2 2024.
- Funds reported $5.25B of Viking Therapeutics stock for Q3 2024, up 23% quarter-over-quarter.
- 94 funds opened new Viking Therapeutics positions in Q3 2024 and 57 closed out, a net change of +37 holders.
- The largest Viking Therapeutics buyer in Q3 2024 was Norges Bank, an estimated $63.8M added.
- The largest Viking Therapeutics seller in Q3 2024 was Goldman Sachs, an estimated $53.8M sold.
Based on aggregated 13F filings for Q3 2024.